Article

Older prostate cancer patients should not be denied curative treatment

Age should not be a barrier to treatment for older men who are relatively healthy but have aggressive prostate cancer, say researchers with University Health Network, Toronto.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
1 expert is featured in this series.
Medcast series
Modern medical office interior with computer and examination table | Image Credit: © New Africa - stock.adobe.com
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
Enzalutamide included in next round of Medicare drug price negotiations
January 17th 2025

Enzalutamide included in next round of Medicare drug price negotiations

Hannah Clarke
The 15 drugs identified in this round of negotiations add to the 10 selected in the first round of negotiations that took place in 2023 and 2024.
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options
January 17th 2025

Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options

Fed Ghali, MD
“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Anktiva targets expanded indication in US and global approvals in EU and UK
January 16th 2025

Anktiva targets expanded indication in US and global approvals in EU and UK

Hannah Clarke
The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.
New Drug Application initiated with FDA for TAR-200 for NMIBC
January 15th 2025

New Drug Application initiated with FDA for TAR-200 for NMIBC

Hannah Clarke Benjamin P. Saylor Kyle Doherty
The NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
© 2025 MJH Life Sciences

All rights reserved.